Optimal quality of vitamin K antagonist therapy in Japanese patients with venous thromboembolism.
Hiramori S, Yamashita Y, Morimoto T, Kadota K, Takase T, Kim K, Oi M, Akao M, Kobayashi Y, Toyofuku M, Inoko M, Tada T, Izumi T, Chen PM, Murata K, Tsuyuki Y, Saga S, Nishimoto Y, Sasa T, Matsuda M, Sakamoto J, Kinoshita M, Togi K, Mabuchi H, Takabayashi K, Nakagawa Y, Kato T, Ono K, Ando K, Kimura T; COMMAND VTE Registry Investigators.
Hiramori S, et al.
J Cardiol. 2022 Nov;80(5):487-494. doi: 10.1016/j.jjcc.2022.07.001. Epub 2022 Jul 23.
J Cardiol. 2022.
PMID: 35882615
Free article.
BACKGROUND: Vitamin K antagonist (VKA) remains an essential option for venous thromboembolism (VTE), although direct oral anticoagulants have become available. However, there is a paucity of data on the optimal intensity and quality of control for VKA in Japanese. METHODS: …
BACKGROUND: Vitamin K antagonist (VKA) remains an essential option for venous thromboembolism (VTE), although direct oral anticoagula …